Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence.
Disease Management
Gout
Patient Preference
Perspective
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
16 Aug 2021
16 Aug 2021
Historique:
received:
12
05
2021
accepted:
01
07
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients' perspectives and preferences. We aimed to investigate patients' perspectives and preferences regarding gout and gout management, and their impacts on adherence to urate lowering therapy (ULT). A paper-based survey was performed in patients with gout seen at the rheumatology outpatient clinics of 16 tertiary hospitals. The survey included questions regarding demographics, comorbidities, gout attacks, current treatment and adherence, and patients' perspectives and preferences regarding gout and gout management. Multivariate regression analysis was performed to determine the factors associated with ULT adherence. Of 809 surveyed patients with gout, 755 (94.5%) were using ULT. Among those using ULT, 89.1% had ≥ 80% adherence to ULT. Majority of the patients knew management strategies to some extent (94.8%), perceived gout as a life-long disease (91.2%), and were making efforts toward practicing at least one lifestyle modification (89.2%). Most patients (71.9%) obtained information about gout management during their clinic visits. Approximately half of the patients (53.6%) preferred managing their disease with both ULT and lifestyle modification, 28.4% preferred ULT only, and 17.4% preferred lifestyle modification only. Adherence was better in patients with older age (odds ratio [OR], 1.03), those with better knowledge of gout management strategies (OR, 3.56), and those who had preference for ULT (OR, 2.07). Patients' perspectives and management preferences had high impacts on adherence to ULT in gout. Consideration of patients' perspectives and preferences is important for achieving the desired clinical outcome in gout.
Sections du résumé
BACKGROUND
BACKGROUND
Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients' perspectives and preferences. We aimed to investigate patients' perspectives and preferences regarding gout and gout management, and their impacts on adherence to urate lowering therapy (ULT).
METHODS
METHODS
A paper-based survey was performed in patients with gout seen at the rheumatology outpatient clinics of 16 tertiary hospitals. The survey included questions regarding demographics, comorbidities, gout attacks, current treatment and adherence, and patients' perspectives and preferences regarding gout and gout management. Multivariate regression analysis was performed to determine the factors associated with ULT adherence.
RESULTS
RESULTS
Of 809 surveyed patients with gout, 755 (94.5%) were using ULT. Among those using ULT, 89.1% had ≥ 80% adherence to ULT. Majority of the patients knew management strategies to some extent (94.8%), perceived gout as a life-long disease (91.2%), and were making efforts toward practicing at least one lifestyle modification (89.2%). Most patients (71.9%) obtained information about gout management during their clinic visits. Approximately half of the patients (53.6%) preferred managing their disease with both ULT and lifestyle modification, 28.4% preferred ULT only, and 17.4% preferred lifestyle modification only. Adherence was better in patients with older age (odds ratio [OR], 1.03), those with better knowledge of gout management strategies (OR, 3.56), and those who had preference for ULT (OR, 2.07).
CONCLUSION
CONCLUSIONS
Patients' perspectives and management preferences had high impacts on adherence to ULT in gout. Consideration of patients' perspectives and preferences is important for achieving the desired clinical outcome in gout.
Identifiants
pubmed: 34402226
pii: 36.e208
doi: 10.3346/jkms.2021.36.e208
pmc: PMC8369315
doi:
Substances chimiques
Gout Suppressants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e208Informations de copyright
© 2021 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1605-12
pubmed: 22034122
J Korean Med Sci. 2014 May;29(5):657-61
pubmed: 24851021
Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760
pubmed: 32391934
Ann Rheum Dis. 2016 Apr;76(4):632-638
pubmed: 27658678
BMJ Open. 2018 Apr 10;8(4):e017542
pubmed: 29643150
BMC Fam Pract. 2016 Aug 19;17(1):114
pubmed: 27542754
Ann Rheum Dis. 2017 Jan;76(1):29-42
pubmed: 27457514
JAMA. 2008 Jul 23;300(4):436-8
pubmed: 18647988
Ann Rheum Dis. 2012 Nov;71(11):1765-70
pubmed: 22863577
Arthritis Rheumatol. 2019 Jun;71(6):991-999
pubmed: 30618180
Rheumatology (Oxford). 2017 Jul 1;56(7):e1-e20
pubmed: 28549177
Nat Rev Dis Primers. 2019 Sep 26;5(1):69
pubmed: 31558729
Am J Med. 2019 Mar;132(3):354-361
pubmed: 30503879
Clin Rheumatol. 2020 Apr;39(4):1061-1063
pubmed: 31836936
Arthritis Care Res (Hoboken). 2017 Aug;69(8):1125-1130
pubmed: 28620968
BMC Complement Altern Med. 2016 Mar 01;16:90
pubmed: 26931313
Korean J Intern Med. 2018 Jan;33(1):228-229
pubmed: 28823114
Arthritis Care Res (Hoboken). 2016 Jan;68(1):26-35
pubmed: 26545701
Rheumatology (Oxford). 2017 Apr 1;56(4):529-533
pubmed: 28082620
Ann Rheum Dis. 2015 Apr;74(4):661-7
pubmed: 24431399
Pharmacotherapy. 2008 Apr;28(4):437-43
pubmed: 18363527
Lancet. 2018 Oct 20;392(10156):1403-1412
pubmed: 30343856
Ann Rheum Dis. 2013 Jun;72(6):826-30
pubmed: 22679303
Ann Rheum Dis. 2012 Sep;71(9):1490-5
pubmed: 22440822
Arthritis Care Res (Hoboken). 2014 Oct;66(10):1551-9
pubmed: 24692321
Semin Arthritis Rheum. 2018 Apr;47(5):689-702
pubmed: 29198878
ACR Open Rheumatol. 2020 Dec;2(12):725-733
pubmed: 33222416